Jeff Terrell
Directeur/Membre du Conseil chez AtaCor Medical, Inc.
Profil
Jeff Terrell is currently a Director at 410 Medical, Inc., AtaCor Medical, Inc., and Cardiosense, Inc. He is also a General Partner at Hatteras Venture Partners since 2019.
Mr. Terrell has an MBA from Duke University, which he obtained in 2013.
He also has an undergraduate degree from Princeton University, which he obtained in 2007.
Postes actifs de Jeff Terrell
| Sociétés | Poste | Début |
|---|---|---|
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | 01/01/2012 |
410 Medical, Inc.
 410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
AtaCor Medical, Inc.
 AtaCor Medical, Inc. Medical SpecialtiesHealth Technology AtaCor Medical, Inc. develops cardiac medical devices. The firm offers AtaCor pacing system. The company was founded by Rick Sanghera, Alan Marcovecchio, and Sean McGeehan in 2014 and is headquartered in San Clemente, CA. | Directeur/Membre du Conseil | - |
Cardiosense, Inc.
 Cardiosense, Inc. Packaged SoftwareTechnology Services The American company's platform leverages novel, multi-sensor devices and proprietary algorithms to mine raw biosignals for unprecedented visibility into cardiac function. Cardiosense has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease, and has introduced an end-to-end patient monitoring and sensor analytics ecosystem that includes the Cardiotag sensor, a medical-grade, multi-sensor wearable device for wireless patient monitoring from in-hospital to home, and the Wavesense platform, a device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data. The company has also developed clinical AI digital biomarkers for early disease detection by applying deep learning to raw physiological waveforms. Amit K. Gupta has been the CEO of the company since 2020. | Directeur/Membre du Conseil | - |
Formation de Jeff Terrell
| Duke University | Masters Business Admin |
| Princeton University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Health Technology |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Finance |
AtaCor Medical, Inc.
AtaCor Medical, Inc. Medical SpecialtiesHealth Technology AtaCor Medical, Inc. develops cardiac medical devices. The firm offers AtaCor pacing system. The company was founded by Rick Sanghera, Alan Marcovecchio, and Sean McGeehan in 2014 and is headquartered in San Clemente, CA. | Health Technology |
Cardiosense, Inc.
Cardiosense, Inc. Packaged SoftwareTechnology Services The American company's platform leverages novel, multi-sensor devices and proprietary algorithms to mine raw biosignals for unprecedented visibility into cardiac function. Cardiosense has developed an advanced signal processing pipeline to identify pre-symptomatic markers of cardiac disease, and has introduced an end-to-end patient monitoring and sensor analytics ecosystem that includes the Cardiotag sensor, a medical-grade, multi-sensor wearable device for wireless patient monitoring from in-hospital to home, and the Wavesense platform, a device-agnostic software to enable aggregation, transmission, and analytics of physiological sensor data. The company has also developed clinical AI digital biomarkers for early disease detection by applying deep learning to raw physiological waveforms. Amit K. Gupta has been the CEO of the company since 2020. | Technology Services |